Graf Acquisition

NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapies. The company utilizes its proprietary SNK platform to produce "Super Natural Killer" cells, which are characterized by high cytotoxicity and purity without the need for genetic modification. Its lead product candidate, SNK01, is currently being evaluated in Phase 1/2a clinical trials for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's, as well as various solid tumors. NKGen Biotech transitioned to the public markets in September 2023 following a business combination with the special purpose acquisition company Graf Acquisition Corp. IV. Headquartered in Santa Ana, California, the company aims to leverage the innate immune system to address significant unmet medical needs in oncology and neurology.